About Cyxone

Cyxone develops new innovative therapies for the treatment of rheumatoid arthritis and multiple sclerosis. Our goal is to improve the quality of life for patients in need of a more effective, convenient and safe treatment option.

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Our mission is to provide better therapies for patients suffering from autoimmune diseases

Press Releases

Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K

May 31, 2023 14:00 (CEST)
Bulletin from the annual general meeting in Cyxone AB on 30 May 2023

May 30, 2023 11:00 (CEST)

Regulatory
Interim Report 1 January to 31 March 2023

May 12, 2023 08:22 (CEST)

Regulatory

About Cyxone

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

Multiple sclerosis (T20K)

Press Releases

Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K

Bulletin from the annual general meeting in Cyxone AB on 30 May 2023

Interim Report 1 January to 31 March 2023

Subscribe to Press Releases